Literature DB >> 26973068

Status of vaccine research and development of vaccines for Nipah virus.

Benjamin A Satterfield1, Brian E Dawes1, Gregg N Milligan2.   

Abstract

Nipah virus (NiV) is a highly pathogenic, recently emerged paramyxovirus that has been responsible for sporadic outbreaks of respiratory and encephalitic disease in Southeast Asia. High case fatality rates have also been associated with recent outbreaks in Malaysia and Bangladesh. Although over two billion people currently live in regions in which NiV is endemic or in which the Pteropus fruit bat reservoir is commonly found, there is no approved vaccine to protect against NiV disease. This report examines the feasibility and current efforts to develop a NiV vaccine including potential hurdles for technical and regulatory assessment of candidate vaccines and the likelihood for financing.
Copyright © 2016 World Health Organization. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Live attenuated vaccine; Nipah virus; Soluble G protein; Subunit vaccine

Mesh:

Substances:

Year:  2016        PMID: 26973068     DOI: 10.1016/j.vaccine.2015.12.075

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  26 in total

Review 1.  Nipah virus matrix protein: expert hacker of cellular machines.

Authors:  Ruth E Watkinson; Benhur Lee
Journal:  FEBS Lett       Date:  2016-07-12       Impact factor: 4.124

Review 2.  Approved Antiviral Drugs over the Past 50 Years.

Authors:  Erik De Clercq; Guangdi Li
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

Review 3.  Nipah Virus Infection.

Authors:  Brenda S P Ang; Tchoyoson C C Lim; Linfa Wang
Journal:  J Clin Microbiol       Date:  2018-05-25       Impact factor: 5.948

Review 4.  Post-exposure prophylactic vaccine candidates for the treatment of human Risk Group 4 pathogen infections.

Authors:  James Logue; Ian Crozier; Peter B Jahrling; Jens H Kuhn
Journal:  Expert Rev Vaccines       Date:  2020-01-30       Impact factor: 5.683

5.  Pathogenic Differences between Nipah Virus Bangladesh and Malaysia Strains in Primates: Implications for Antibody Therapy.

Authors:  Chad E Mire; Benjamin A Satterfield; Joan B Geisbert; Krystle N Agans; Viktoriya Borisevich; Lianying Yan; Yee-Peng Chan; Robert W Cross; Karla A Fenton; Christopher C Broder; Thomas W Geisbert
Journal:  Sci Rep       Date:  2016-08-03       Impact factor: 4.379

Review 6.  Chimpanzee adenoviral vectors as vaccines for outbreak pathogens.

Authors:  Katie Ewer; Sarah Sebastian; Alexandra J Spencer; Sarah Gilbert; Adrian V S Hill; Teresa Lambe
Journal:  Hum Vaccin Immunother       Date:  2017-10-30       Impact factor: 3.452

Review 7.  Vaccines for epidemic infections and the role of CEPI.

Authors:  Stanley A Plotkin
Journal:  Hum Vaccin Immunother       Date:  2017-04-04       Impact factor: 3.452

8.  Antiviral Lipopeptide-Cell Membrane Interaction Is Influenced by PEG Linker Length.

Authors:  Marcelo T Augusto; Axel Hollmann; Matteo Porotto; Anne Moscona; Nuno C Santos
Journal:  Molecules       Date:  2017-07-15       Impact factor: 4.411

9.  Fusion Inhibitory Lipopeptides Engineered for Prophylaxis of Nipah Virus in Primates.

Authors:  Cyrille Mathieu; Matteo Porotto; Tiago N Figueira; Branka Horvat; Anne Moscona
Journal:  J Infect Dis       Date:  2018-06-20       Impact factor: 5.226

Review 10.  Cryptic etiopathological conditions of equine nervous system with special emphasis on viral diseases.

Authors:  Rakesh Kumar; Rajendra D Patil
Journal:  Vet World       Date:  2017-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.